BridgeMD
New treatment option for Coronary Microvascular Disease
Official title Qishenyiqi Dripping Pill for Coronary Microvascular Disease
ClinicalTrials.gov ID: NCT06699420
What this study is testing
What is Qishenyiqi dripping pills 1 bag, three times a day?
Qishenyiqi dripping pills 1 bag, three times a day is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for coronary microvascular disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To investigate the efficacy and safety of Qishenyiqi in patients with microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Qishenyiqi on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 to 75
You may be able to join if
- Repeated chest pain attacks with typical exertional angina pectoris or resting angina pectoris attacks;
- Coronary normal or stenosis \< 20%;
- Ischemic depression in ST segment during resting or exercise;
- Blood flow reserve (CFR) of the anterior descending coronary artery \< 2.0;
- people or their guardians agreed to participate in this study.
You likely can't join if
- Previous myocardial infarction or PCI or CABG treatment;
- A history of heart failure;
- Severe arrhythmia;
- Refractory hypertension or hypertension accompanied by left ventricular wall thickness \> 12 mm;
- Familial hypercholesterolemia;
- Takayasu arteritis, Kawasaki disease or coronary artery malformation;
See the full eligibility criteria
- Repeated chest pain attacks with typical exertional angina pectoris or resting angina pectoris attacks;
- Coronary normal or stenosis \< 20%;
- Ischemic depression in ST segment during resting or exercise;
- Blood flow reserve (CFR) of the anterior descending coronary artery \< 2.0;
- people or their guardians agreed to participate in this study.
- Previous myocardial infarction or PCI or CABG treatment;
- A history of heart failure;
- Severe arrhythmia;
- Refractory hypertension or hypertension accompanied by left ventricular wall thickness \> 12 mm;
- Familial hypercholesterolemia;
- Takayasu arteritis, Kawasaki disease or coronary artery malformation;
- Pregnant or nursing, or having the intention to give birth within one year;
- Hepatic or renal dysfunction;
- Allergic to contrast agents or traditional Chinese medicines;
- Patients who participated in clinical research of other drugs within 3 months before being selected.
The study team makes the final eligibility decision.
Where it's taking place
- Jinan, Shandong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Jinan, Shandong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.